SCHEMBL4385213

SCHEMBL4385213

NOCc1nc2cc(Cl)ccc2o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ MAPT P10636 2/20 0.56
▸ LMNA P02545 2/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ THRB P10828 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ POLB P06746 1/20 0.51
▸ PSMB8 P28062 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ CASP3 P42574 2/20 0.46
▸ SENP7 Q9BQF6 2/20 0.46
▸ SENP6 Q9GZR1 2/20 0.46
▸ KDM4E B2RXH2 5/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ HPGD P15428 2/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16425157 0.84 MEN1 (0.61) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL11336728 0.81 MEN1 (0.66) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL16421073 0.80 MEN1 (0.57) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL4285418 0.80 MEN1 (0.64) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL30612632 0.80 MEN1 (0.64) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL4899456 0.79 MEN1 (0.68) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL11449646 0.78 MEN1 (0.62) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL21104415 0.78 MEN1 (0.62) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL22042882 0.78 MEN1 (0.62) KMT2AMEN1MAPTLMNACYP1A2
SCHEMBL805061 0.78 MEN1 (0.71) KMT2AMEN1MAPTLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
EP-2040698-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2009-04-01 — — EP disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 — — WO disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 KMT2A 2079/4885MEN1 3694/4885MAPT 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback